Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
INPACT: an integrated service in preclinical pharmacology
Home . Service . INPACT: integrated service in preclinical pharmacology
Proof of concept in preclinical pharmacology
Establishing proof of concept in preclinical pharmacology is a critical step in the drug discovery process. This is one of the decisive factors in setting the therapeutic indication(s) targeted in clinical models and in the decision to continue a new product through the regulatory preclinical and clinical steps.
For more than 25 years, Oncodesign has been a player known for its experience and excellence in preclinical pharmacology, particularly in vitro and in vivo testing, PK, PK/PD relationships and pharmaco-imaging applied to the identification and qualification of the therapeutic potential of many different approaches and techniques – chemical entities, peptides, oligonucleotides, biologics, gene and cell therapies, oncolytic viruses, vaccines and more.
A partnership of choice for your therapeutic innovation
INPACT is an integrated service in preclinical pharmacology to support you and bring our expertise in guiding and establishing proof of concept for your therapeutic discovery and innovation programs in oncology, immuno-inflammation and COVID-19 pathology.
INPACT – Oncology, a continuum of expertise in anti-cancer pharmacology and immuno-oncology, developed within our technical innovation platforms TOT® (phenotyping), Predict® – Oncology (syngeneic, CDX, chemo-induced models), Chi-mice® (humanized models, PDX), Pharmimage® (in vivo pharmaco-imaging), combined with our DMPK and bioanalysis capabilities.
INPACT – Inflammation, a broad range of pharmacological expertise in in vitro and in vivo models of acute or chronic inflammation, as well as fibrosis, for many organs, developed within our technical innovation platform Predict® – Inflammatory diseases, etand combined with our DMPK and bioanalysis capabilities.
INPACT – Covid-19, an extensive in vitro and in vivo preclinical pharmacological evaluation of SARS-CoV-2 infection in rodent and non-human primate models, combined with our DMPK and bioanalysis capabilities.
The pharmaceutical culture, the quality and the expertise of a team of experienced and dedicated scientists to successfully complete your project.
An agile, flexible “one-stop shop” model aimed at optimizing production times and delivering results.
A definition of a preclinical pharmacological development plan in line with the target product profile.
Personal project management tailored to your needs and challenges. Regular discussions and exchanges through project meetings and steering committees so you can make your decisions within the given deadlines.